Heart drug fails: what the trial result tells us

In a condition called ATTR-CM (transthyretin amyloid cardiomyopathy), a protein called transthyretin misfolds and accumulates in heart tissue, making the heart stiffer and less able to pump. Two types of drugs are being tested: silencers that block production of the harmful protein, and stabilisers that prevent the protein from misfolds in the first place.

AstraZeneca tested a silencer on top of a stabiliser. The outcome was unexpected. The researchers reported that patients already taking a stabiliser saw no additional benefit from adding the silencer. That effect was powerful enough to sink the entire phase 3 study. Results were presented at the European Society of Cardiology meeting.

What this means for combination therapy

The findings suggest that stabilisers may already intervene on the transthyretin protein so effectively that adding a silencer provides little extra benefit. That has broad implications for how future combination trials in this space are designed. It also serves as a reminder that a drug with a stronger theoretical mechanism does not always outperform an existing treatment in practice.

Alnylam, which is developing a comparable silencer for both heart and nerve complications caused by transthyretin accumulation, is watching the results closely. Whether this failure affects Alnylam’s approach remains unclear. Experts note that the patient populations and drugs involved are not identical, making direct comparisons difficult.

No immediate change for patients

For people currently living with ATTR-CM, existing stabilisers remain available and unchanged. But the trial failure underlines how difficult it is to improve on current treatments for this condition. For the longevity field, the result is a useful lesson: combining mechanistically sound interventions does not guarantee additive benefit.

Read the original article